EBGLYSS Improves Hand and Foot Atopic Dermatitis Symptoms

INDIANAPOLIS, Sept. 30, 2026 /CourierPR/ -- Eli Lilly and Company today announced significant and rapid improvements in skin clearance, itch, and pain for adults and adolescents with moderate-to-severe hand and foot atopic dermatitis (AD), based on data from the Phase 3b ADtouch study. The study, which evaluated Eli Lilly's EBGLYSS (lebrikizumab-lbkz) monotherapy, showed that more than half of patients achieved clear or almost clear skin on their hands and feet by Week 16, with significant skin clearance as early as one month.

EBGLYSS, an interleukin-13 (IL-13) inhibitor with high binding affinity and a slow dissociation rate, significantly reduced itch and pain, with significant itch improvements as early as two weeks. In a first-of-its-kind patient satisfaction data, nearly eight out of 10 patients treated with EBGLYSS reported being satisfied or very satisfied with hand clearance at Week 16.

The ADtouch clinical trial evaluated EBGLYSS monotherapy in adults and adolescents with moderate-to-severe hand and foot AD who had an inadequate response to topical therapies. In the ADtouch clinical trial, participants were randomized to receive placebo or EBGLYSS every two weeks. The trial assessed physician- and patient-reported outcomes across skin clearance, itch, pain, patient satisfaction with hand clearance, and quality of life.

Patients enrolled in the study had moderate-to-severe hand and foot involvement, with most having limited AD across the rest of the body. At baseline, patients were living with severe itch of the hands and feet, moderate pain, and substantial impairment in quality of life, despite limited overall skin involvement.

EBGLYSS is an injectable medicine used to treat adults and children 12 years of age and older with moderate-to-severe atopic dermatitis (AD) that is not well controlled with topical prescription therapies, or who cannot use topical therapies. The approved maintenance dose of EBGLYSS is 250 mg every four weeks (EU and U.S.) or 250 mg every eight weeks (U.S.), after taking EBGLYSS every two weeks for the four-month initial dosing phase (or later once achieving adequate clinical response).

The safety of EBGLYSS in ADtouch was consistent with the known profile in adult and adolescent patients, with no new safety signals observed. Treatment-emergent adverse events were reported in 41.8% of patients receiving EBGLYSS and 39.6% receiving placebo, and all were mild or moderate in severity. The most common (≥5%) adverse reactions reported with EBGLYSS were nasopharyngitis and upper respiratory tract infection.

Lilly has submitted these data to the U.S. Food and Drug Administration (FDA) and plans to submit to select global regulatory authorities for a potential label update to include these data for localized AD with moderate-to-severe hand and foot involvement. Almirall will also present EBGLYSS data at the European Academy of Dermatology and Venereology (EADV) Congress, including five-year results from the Phase 3b ADlong trial, which reinforce previously reported four-year ADlong results for EBGLYSS.

EBGLYSS is approved in the U.S. to treat adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe eczema (atopic dermatitis) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. In June 2026, the U.S. FDA approved a regimen of one maintenance dose every eight weeks of a single injection (250 mg/2 mL) of EBGLYSS for subcutaneous use, building on its already approved once-monthly maintenance dose. EBGLYSS can be used with or without topical corticosteroids.

Lilly has exclusive rights for development and commercialization of EBGLYSS in the U.S. and the rest of the world outside Europe. Almirall has licensed the rights to develop and commercialize EBGLYSS for the treatment of dermatology indications, including atopic dermatitis, in Europe.

The Phase 3 program in atopic dermatitis consists of seven key global studies, including two monotherapy studies (ADvocate 1 and 2), a combination study with topical corticosteroids (ADhere), long-term extension (ADjoin) and adolescent open-label (ADore) studies. The program also includes a study assessing the impact of EBGLYSS on vaccine immune response in adults (ADopt-VA). EBGLYSS has been studied in patients with skin of color (ADmirable) and in dupilumab-experienced patients (ADapt).

EBGLYSS was approved in the U.S., Japan and Canada in 2024 and in the European Union in 2023. EBGLYSS is a first-line biologic treatment, administered with or without topical corticosteroids, that offers every-four-week (EU and U.S.) or every-eight-week (U.S.) maintenance dosing for adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis that is not well-controlled with topical prescription therapies.

Lilly is committed to serving patients living with moderate-to-severe atopic dermatitis and is working to enable broad first-line biologic access to EBGLYSS for patients not well-controlled with topical prescription therapy through commercial insurance. Lilly has coverage with all three major national pharmacy benefit managers, and EBGLYSS is covered on nearly 95% of national commercial plans.